---
title: "Artelo Biosciences | 10-Q: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286461669.md"
datetime: "2026-05-14T20:17:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286461669.md)
  - [en](https://longbridge.com/en/news/286461669.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286461669.md)
---

# Artelo Biosciences | 10-Q: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -4.

EBIT: As of FY2026 Q1, the actual value is USD -2.566 M.

Artelo Biosciences, Inc. operates as a single reporting segment focused on life science, specifically the development of therapeutics targeting lipid-signaling modulation pathways, including the endocannabinoid system (ECS).

#### Revenue

Artelo Biosciences, Inc. has not generated any revenue since its inception and expects to continue incurring losses in the foreseeable future.

#### Operating Expenses

-   Total operating expenses increased to $2,689 thousand for the three months ended March 31, 2026, from $2,379 thousand for the same period in 2025, representing an increase of $310 thousand.
-   General and administrative expenses increased to $1,916 thousand in Q1 2026 from $995 thousand in Q1 2025, primarily due to increased professional fees related to financing activities and increases in stock-based compensation service costs.
-   Research and development expenses decreased to $773 thousand in Q1 2026 from $1,384 thousand in Q1 2025, attributed to the timing and level of research being conducted.

#### Net Loss

-   Net loss increased to -$2,958 thousand for the three months ended March 31, 2026, compared to -$2,372 thousand for the same period in 2025.

#### Other Income (Expense)

-   Total other income (expense) was -$269 thousand in Q1 2026, a decrease from $7 thousand in Q1 2025.

#### Liquidity and Capital Resources

-   Cash and cash equivalents were $10,273 thousand as of March 31, 2026, significantly up from $600 thousand as of December 31, 2025.
-   Working capital improved to $4,593 thousand as of March 31, 2026, from -$3,349 thousand as of December 31, 2025, primarily due to financing activities during the current quarter.
-   Total current assets were $10,421 thousand as of March 31, 2026, compared to $695 thousand as of December 31, 2025.
-   Total current liabilities were $5,828 thousand as of March 31, 2026, compared to $4,044 thousand as of December 31, 2025.

#### Cash Flows

-   Cash flows used in operating activities decreased to -$1,191 thousand for the three months ended March 31, 2026, from -$1,597 thousand for the same period in 2025.
-   Cash flows provided by financing activities increased significantly to $10,860 thousand in Q1 2026, primarily from $10,033 thousand in net proceeds from common shares, $593 thousand from convertible notes, and $234 thousand from warrant exercises, compared to $0 thousand in Q1 2025.

#### Outlook and Strategy

Artelo Biosciences, Inc. expects to continue incurring future research and development and general and administrative expenses, with R&D levels dependent on clinical development and available funding. The company will require additional funds through equity, debt, or licensing to continue operations, as there is substantial doubt about its ability to continue as a going concern within one year. Recent financing activities, including a private placement offering that generated gross proceeds of $10,997 thousand, are intended for working capital and general corporate purposes, with shelf registration statements allowing the company to sell up to $75,000 thousand in securities.

### Related Stocks

- [ARTL.US](https://longbridge.com/en/quote/ARTL.US.md)

## Related News & Research

- [Artelo Biosciences Q1 net loss widens, R&D expenses fall](https://longbridge.com/en/news/286462732.md)
- [Copart Reports Third Quarter Fiscal 2026 Financial Results | CPRT Stock News](https://longbridge.com/en/news/287267665.md)
- [Yext to Announce First Quarter Fiscal Year 2027 Financial Results on June 2, 2026 | YEXT Stock News](https://longbridge.com/en/news/286970613.md)
- [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md)
- [Crombie Reit Announces May 2026 Monthly Distribution | CROMF Stock News](https://longbridge.com/en/news/286603129.md)